$EXEL (Exelixis, Inc.)

$EXEL {{ '2016-09-08T07:38:16+0000' | timeago}} • Announcement

Drug company $EXEL announced the outcome from the first interim analysis of CELESTIAL, a phase 3 trial of cabozantinib versus placebo in patients with advanced liver cancer, HCC, who have been previously treated with sorafenib. The Independent Data Monitoring Committee determined that the study should continue without modifications per protocol.

$IPXL {{ '2017-10-17T12:55:44+0000' | timeago}} • Announcement

$IPXL has entered into a definitive agreement with Amneal Pharmaceuticals, under which the companies will merge to create the largest generics business in the US. Pursuant to the all-stock transaction, Amneal shareholders will own 75% and Impax shareholders will own 25% of the new company's pro forma shares.

$MDXG {{ '2017-10-17T12:38:30+0000' | timeago}} • Announcement

$MDXG, a pharmaceutical firm, said it received green signal from the FDA to proceed with the Investigational New Drug study of AmnioFix, an injectable formulation for  the treatment of knee osteoarthritis, in comparison with saline placebo. The company expects patient enrollment in the the phase-2B study to commence next quarter.

$JNJ {{ '2017-10-17T12:09:28+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q3 2017 Highlights

$UNH {{ '2017-10-17T11:55:37+0000' | timeago}} • Infographic

$UNH UnitedHealth Earnings AlphaGraphics: Q3 2017 Highlights

$JNJ {{ '2017-10-17T11:47:16+0000' | timeago}} • Announcement

$JNJ raised its sales and adjusted earnings guidance for FY17. The New Brunswick, NJ-based healthcare giant now expects sales for the period to be in the range of $76.1 - 76.5Bil, verses the prior guidance of $75.8 - 76.1Bil. Adjusted earnings is anticipated to be $7.25 - $7.30 per share, compared to the prior guidance of $7.12 - $7.22 per share.

$JNJ {{ '2017-10-17T11:36:50+0000' | timeago}} • Announcement

Kicking off the earnings season in healthcare sector, $JNJ reported 10.3% growth in its sales to $19.7Bil in 3Q17. Adjusted earnings also rose double digits to $5.2Bil, or $1.90 per share, driven by strong growth in Pharma unit, as well as Actelion acquisition. On a GAAP basis, earnings fell 12% to $3.8Bil, or $1.37 per share.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$LLY {{ '2017-10-16T19:27:03+0000' | timeago}} • Announcement

The BoD of $LLY declared a dividend for 4Q17 of $0.52 per share, payable on Dec. 8, 2017 to shareholders as of Nov. 15, 2017.

$REGN {{ '2017-10-16T14:56:28+0000' | timeago}} • Announcement

$REGN and $SNY announced positive results from a Phase 2 study of dupilumab in adults with active moderateto-severe eosinophilic esophagitis (a condition that causes swallowing difficulty). The study showed that patients who received dupilumab weekly reported a significant improvement in the ability to swallow versus placebo.

$JNJ {{ '2017-10-16T14:43:30+0000' | timeago}} • Announcement

$JNJ said Janssen Biotech Inc. has received FDA approval for an expanded indication for STELARA for the treatment of adolescents with plaque psoriasis.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$LLY {{ '2017-10-12T14:50:24+0000' | timeago}} • Announcement

FDA grants priority review for $LLY's breast cancer drug Verzenio, which was approved by the agency on Sept. 28. 2017. Now, FDA will speed up the review and will take action within eight months.  On Oct. 10, 2017, Lilly announced that Verzenio failed in the Phase 3 study for treating advanced lung cancer.

$MCK {{ '2017-10-11T18:31:37+0000' | timeago}} • Announcement

Biologics, a $MCK Specialty Health oncology pharmacy services company, has been selected by $LLY to be in the limited distribution network for Verzenio (abemaciclib), $LLY's first oral oncolytic indicated for metastatic breast cancer. Verzenio obstructs growth of cancer cells by specifically blocking cyclin-dependent kinases, CDK4 and CDK6.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$MDXG {{ '2017-10-10T14:24:36+0000' | timeago}} • Announcement

$MDXG announced its preliminary revenue results for 3Q17. The company recorded revenue of $84.6MM, up 31% over 3Q16. Revenue from the direct sales force is in excess of 95% of total revenue with revenue from distributors and Original Equipment Manufacturer (OEM) accounts below 5% of total revenue. YTD revenue grew 33% to $233.6MM vs. last year.

$LLY {{ '2017-10-10T13:44:54+0000' | timeago}} • Announcement

$LLY's advanced lung cancer treatment drug Verzenio flunks in meeting the end goal of overall survival among the 453 patients in the Phase 3 JUNIPER trial study. The most common adverse events experienced by these patients were diarrhea, fatigue, decreased appetite, and nausea. Last month, FDA approved Verzenio for the treatment of breast cancer.

$Q {{ '2017-10-10T12:37:04+0000' | timeago}} • Announcement

$Q announced the pricing of the offering of €420MM in gross proceeds of senior notes to be issued by its subsidiary, Quintiles IMS Incorporated. The notes will bear interest at a rate of 2.875% and will pay interest semi-annually in arrears on March 15 and Sept 15 of each year, beginning on March 15, 2018. The notes will mature on Sept 15, 2025.

$Q {{ '2017-10-10T12:14:55+0000' | timeago}} • Announcement

$Q announced the launch of an underwritten, secondary public offering of 9MM common shares by certain of its existing stockholders, including affiliates of TPG Global, CPP Investment Board Private Holdings, investment funds associated with Bain Capital Investors, and Leonard Green & Partners. $Q plans to repurchase from underwriter 4MM shares.

$MDXG {{ '2017-10-09T12:45:46+0000' | timeago}} • Announcement

$MDXG's BoD has authorized a $10MM increase in the company's share repurchase program, bringing the total authorized to $110MM since the commencement in May 2014.

$LLY {{ '2017-10-06T18:13:20+0000' | timeago}} • Announcement

The U.S. Patent and Trademark Office (PTO) ruled in favor of $LLY for its cancer drug Alimta. The review was initiated by Neptune Generics and Sandoz Inc and PTO concluded that claims of the Alimta vitamin regimen patent are valid. If the patent is upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022.

Recent Transcripts

XON (Intrexon Corporation)
Wednesday, August 9 2017 - 9:30pm
VRML (Vermillion, Inc.)
Wednesday, August 9 2017 - 8:30pm
CRL (Charles River Laboratories International, Inc.)
Wednesday, August 9 2017 - 12:30pm
IPXL (Impax Laboratories Inc.)
Wednesday, August 9 2017 - 12:30pm
ATRS (Antares Pharma Inc.)
Tuesday, August 8 2017 - 12:30pm
Q (Quintiles Transnational Holdings Inc.)
Thursday, August 3 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
EXEL (Exelixis, Inc.)
Wednesday, August 2 2017 - 9:00pm
AMRN (Amarin Corporation plc)
Wednesday, August 2 2017 - 12:00pm
RIGL (Rigel Pharmaceuticals, Inc.)
Tuesday, August 1 2017 - 9:00pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
SNMX (Senomyx Inc.)
Thursday, July 27 2017 - 9:00pm
MDXG (MiMedx Group, Inc.)
Thursday, July 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
ICLR (ICON Public Limited Company)
Thursday, July 27 2017 - 1:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
GSK (GlaxoSmithKline plc)
Wednesday, July 26 2017 - 1:00pm
EXAS (Exact Sciences Corporation)
Tuesday, July 25 2017 - 9:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm

AlphaGraphics you may like